Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis

MLA

A. V. Shcheprov, et al. “Cardiovascular Outcomes Associated with a New Once-Weekly GLP-1 Receptor Agonist vs. Traditional Therapies for Type 2 Diabetes: A Simulation Analysis.” Diabetes, Obesity and Metabolism, vol. 13, Sept. 2011, pp. 921–27. EBSCOhost, https://doi.org/10.1111/j.1463-1326.2011.01430.x.

APA

A. V. Shcheprov, Julia A Gaebler, Kristina S. Boye, S. Bruce, B. R. Peskin, & David G. Maggs. (2011). Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis. Diabetes, Obesity and Metabolism, 13, 921–927. https://doi.org/10.1111/j.1463-1326.2011.01430.x

Chicago

A. V. Shcheprov, Julia A Gaebler, Kristina S. Boye, S. Bruce, B. R. Peskin, and David G. Maggs. 2011. “Cardiovascular Outcomes Associated with a New Once-Weekly GLP-1 Receptor Agonist vs. Traditional Therapies for Type 2 Diabetes: A Simulation Analysis.” Diabetes, Obesity and Metabolism 13 (September): 921–27. doi:10.1111/j.1463-1326.2011.01430.x.